COMMUNIQUÉS West-GlobeNewswire

Avadel Pharmaceuticals to Report First Quarter 2018 Results

24/04/2018 - 13:30

DUBLIN, Ireland, April 24, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL ), today announced it will report its first quarter 2018 financial results on Wednesday, May 2, 2018, before the market open. [...]

Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy at the 2018 Annual Cure SMA Conference

24/04/2018 - 13:30

SOUTH SAN FRANCISCO, Calif., April 24, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK ) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular [...]

Orion Group Interim Report January-March 2018

24/04/2018 - 11:01

ORION CORPORATION INTERIM REPORT JANUARY-MARCH 2018 24 APRIL 2018 at 12:00 EEST Orion Group Interim Report January-March 2018 Orion's net sales for continuing operations in January-March 2018 totalled EUR 247 million ( [...]

ViaDerma, Inc. Enters into a $250,000 Initial Sales Agreement with Vage Nigeria Ltd.

24/04/2018 - 11:00

LOS ANGELES, April 24, 2018 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink:VDRM), is pleased to announce it has entered into a $250,000 initial sales agreement with Vage Nigeria Ltd. (“Vage”), a brand support [...]

Galapagos reports initiation of FALCON clinical trial in cystic fibrosis

24/04/2018 - 08:46

Our first triple combination investigational therapy for CF patients combination of '2451+'2222+'2737 multiple centers in Europe topline results expected Q3 2018 Mechelen, Belgium; 24 April 2018; 08.45 AM CET - [...]

Shire plc : Rule 2.9 Announcement

24/04/2018 - 08:01

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 24 April 2018 [...]

Lysogene Signs Partnership Agreement with Dr. Hervé Moine, Researcher at the IGBMC(1) and the SATT(2) Conectus Alsace, in the Fragile X Syndrome

24/04/2018 - 08:00

Development of a gene therapy product for the treatment of patients with Fragile X syndrome Implementation of the project through a unique partnership First results anticipated in 2019 CAMBRIDGE, Mass. and PARIS, April [...]

Interim Report January-March 2018

24/04/2018 - 08:00

Summary Q1 IN BRIEF The study design for PledOx ® Phase III program has been approved by the UK Medicines Agency MHRA and accepted by the US FDA and the Central Ethics Committee of the United States PledOx ® shows [...]

Notice of annual shareholders’ meeting in Saniona AB

24/04/2018 - 08:00

PRESS RELEASE April 24, 2018 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders in Saniona [...]

Notification from Oasmia Pharmaceutical AB

24/04/2018 - 08:00

Uppsala, Sweden, April 24, 2018 – Oasmia Pharmaceutical AB hereby issues a notification regarding the issuance of the agenda for EMA’s CHMP meeting April 23 – 26. Instead of the announced oral explanation, Oasmia will [...]

Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1

24/04/2018 - 07:31

Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1 Paris - 24 th April 2018 -- Elias Zerhouni, M.D., Head of [...]

Départ à la retraite du Président Monde de la R&D de Sanofi, Elias Zerhouni ; L'entreprise nomme John Reed pour lui succéder à compter du 1er juillet

24/04/2018 - 07:31

Communiqué de presse Source : Sanofi (EURONEXT : SAN) (NYSE : SNY) Départ à la retraite du Président Monde de la R&D de Sanofi, Elias Zerhouni ; L'entreprise nomme John Reed pour lui succéder à compter du 1 er [...]

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

24/04/2018 - 07:01

REGULATED INFORMATION GHENT, Belgium, 24 April 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]

Targovax ASA: Invitation to first quarter 2018 results presentation Thursday 3 May

24/04/2018 - 07:01

Oslo, Norway, 24 April 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its first quarter 2018 results on Thursday, 3 May [...]

MDxHealth Provides First Quarter 2018

24/04/2018 - 07:01

NEWS RELEASE REGULATED INFORMATION INTERIM TRADING UPDATE MDxHealth Provides First Quarter 2018 Business Update IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, April 24, 2018 - MDxHealth SA ("MDxHealth, or the "Company [...]

MDxHealth publie ses résultats du premier trimestre 2018

24/04/2018 - 07:01

COMMUNIQUÉ DE PRESSE INFORMATIONS REGLEMENTÉES RAPPORT D'ACTIVITÉS TEMPORAIRE MDxHealth publie ses résultats du premier trimestre 2018 IRVINE, CA, et HERSTAL, BELGIQUE - 07h00 CEST, mardi 24 avril 2018 - MDxHealth SA [...]

argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting

24/04/2018 - 07:01

Eight-week follow-up data show separation of clinical efficacy scores between treatment group and placebo group through the duration of study Total and pathogenic IgG reduction correlates with disease score improvements [...]

Axiom Real-Time Metrics Exhibiting Fusion eClinical Suite at Clinical Operations in Oncology Trials West

24/04/2018 - 01:11

TORONTO, April 23, 2018 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics, premier provider of unified eClinical solutions and services, is exhibiting at Clinical Operations in Oncology Trials West on April 24 th and 25 th in [...]

Immuron CEO to Present at RedChip Global Online Growth Conference

24/04/2018 - 00:57

MELBOURNE, Australia, April 23, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ: IMRN ), Australian microbiome biopharmaceutical company focused on developing and commercialising orally delivered targeted [...]